Almost 4 million people are infected with hepatitis C virus (HCV) in the United States alone, with 170 million infected worldwide. It is the leading cause of liver transplantation in the US. Although infection is initially asymptomatic, HCV often leads to chronic liver disease, cirrhosis, and/or liver cancer. Many cases are treatable with combination therapy (interferon, ribavirin, and new protease inhibitors), but efficacy is dependent on the infecting strain and there is currently no vaccine. Without more effective antiviral and immunological treatments, the Centers for Disease Control and Prevention (CDC) predicts that deaths due to HCV will double or triple in the next 15 to 20 years due to prolonged disease and continued spread. The high prevalence of infection, lack of highly effective HCV-specific inhibitors, and poor response rate to the current treatment underscore the importance of developing new therapeutic strategies. The mechanism of viral entry is an important subject of study with respect to preventing and treating infection. Two of the four HCV structural proteins, envelope 1 (E1) and envelope 2 (E2), heterodimerize on the surface of the virion. Experimental evidence supports the roles of E1 and E2 in receptor binding, virus-cell fusion, and entry into the host cell. These factors make E1 and E2 key determinants of pathogenicity and optimal targets of vaccine design. We hypothesize that a thorough biophysical understanding of E2, as well as improvements in the available biochemical tools for the study of HCV E2 will provide a significant advancement in the understanding of viral infection.
Subject (authority = RUETD)
Topic
Microbiology and Molecular Genetics
RelatedItem (type = host)
TitleInfo
Title
Rutgers University Electronic Theses and Dissertations
Rutgers University. Graduate School - New Brunswick
AssociatedObject
Type
License
Name
Author Agreement License
Detail
I hereby grant to the Rutgers University Libraries and to my school the non-exclusive right to archive, reproduce and distribute my thesis or dissertation, in whole or in part, and/or my abstract, in whole or in part, in and from an electronic format, subject to the release date subsequently stipulated in this submittal form and approved by my school. I represent and stipulate that the thesis or dissertation and its abstract are my original work, that they do not infringe or violate any rights of others, and that I make these grants as the sole owner of the rights to my thesis or dissertation and its abstract. I represent that I have obtained written permissions, when necessary, from the owner(s) of each third party copyrighted matter to be included in my thesis or dissertation and will supply copies of such upon request by my school. I acknowledge that RU ETD and my school will not distribute my thesis or dissertation or its abstract if, in their reasonable judgment, they believe all such rights have not been secured. I acknowledge that I retain ownership rights to the copyright of my work. I also retain the right to use all or part of this thesis or dissertation in future works, such as articles or books.